Revolution Medicines (RVMD) Total Liabilities (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Total Liabilities of $753.8 million for Q1 2026, up 162.47% year-over-year from $287.2 million in Q1 2025, and up 4.23% quarter-over-quarter from $723.2 million in Q4 2025.
Revolution Medicines (RVMD) Total Liabilities (2019 - 2026) Analysis & Trends
Revolution Medicines' Total Liabilities history runs 8 years deep, the most recent figure standing at $753.8 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 162.47% year-over-year to $753.8 million; the TTM figure through Mar 2026 stood at $753.8 million (up 162.47% YoY), while the FY2025 annual figure was $723.2 million, up 146.75% from the prior year.
- Total Liabilities for Q1 2026 stood at $753.8 million, up from $723.2 million in the prior quarter.
- The five-year high for Total Liabilities was $753.8 million in Q1 2026, with the low at $121.0 million in Q1 2023.
- The 5-year median for Total Liabilities is $189.6 million (2024), against an average of $295.8 million.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities decreased 8.16% in 2023, then surged 233.01% in 2025.
- Revolution Medicines' Total Liabilities stood at $126.7 million in 2022, then soared by 85.82% to $235.5 million in 2023, then rose by 24.45% to $293.1 million in 2024, then soared by 146.75% to $723.2 million in 2025, then advanced by 4.23% to $753.8 million in 2026.
- Business Quant data shows RVMD's Total Liabilities at $753.8 million in Q1 2026, $723.2 million in Q4 2025, and $655.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 384.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.72 Bn |
| Mar 31, 2026 | 753.82 Mn |
| Dec 31, 2025 | 723.21 Mn |
| Sep 30, 2025 | 655.02 Mn |
| Jun 30, 2025 | 564.20 Mn |
| Mar 31, 2025 | 287.20 Mn |
| Dec 31, 2024 | 293.10 Mn |
| Sep 30, 2024 | 196.70 Mn |
| Jun 30, 2024 | 189.59 Mn |
| Mar 31, 2024 | 182.90 Mn |
| Dec 31, 2023 | 235.51 Mn |
| Sep 30, 2023 | 146.77 Mn |
| Jun 30, 2023 | 142.87 Mn |
| Mar 31, 2023 | 121.03 Mn |
| Dec 31, 2022 | 126.74 Mn |
| Sep 30, 2022 | 144.49 Mn |
| Jun 30, 2022 | 133.96 Mn |
| Mar 31, 2022 | 131.78 Mn |
| Dec 31, 2021 | 135.42 Mn |
| Sep 30, 2021 | 96.77 Mn |